These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 31078440)

  • 1. Comparing drug interaction frequencies of various hepatitis C treatment regimens among monoinfected patients.
    Ahmed A; Schriever C; Britt N; Yager J; Amin R; McGuey L; Patel N
    Ann Hepatol; 2019; 18(4):601-606. PubMed ID: 31078440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of drug-drug interactions upon addition of simeprevir- or sofosbuvir-containing treatment to medication profiles of patients with HIV and hepatitis C coinfection.
    Patel N; Nasiri M; Koroglu A; Amin R; McGuey L; McNutt LA; Roman M; Miller C
    AIDS Res Hum Retroviruses; 2015 Feb; 31(2):189-97. PubMed ID: 25432275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Cross-Sectional Study Comparing the Frequency of Drug Interactions After Adding Simeprevir- or Sofosbuvir-Containing Therapy to Medication Profiles of Hepatitis C Monoinfected Patients.
    Patel N; Nasiri M; Koroglu A; Bliss S; Davis M; McNutt LA; Miller C
    Infect Dis Ther; 2015 Jan; 4(1):67-78. PubMed ID: 25708155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment.
    Evon DM; Golin CE; Stewart P; Fried MW; Alston S; Reeve B; Lok AS; Sterling RK; Lim JK; Reau N; Sarkar S; Nelson DR; Reddy KR; Di Bisceglie AM
    Contemp Clin Trials; 2017 Jun; 57():58-68. PubMed ID: 28342989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.
    Buggisch P; Wursthorn K; Stoehr A; Atanasov PK; Supiot R; Lee J; Ting J; Petersen J
    PLoS One; 2019; 14(4):e0214795. PubMed ID: 30946776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials.
    Gane EJ; Pianko S; Roberts SK; Thompson AJ; Zeuzem S; Zuckerman E; Ben-Ari Z; Foster GR; Agarwal K; Laursen AL; Gerstoft J; Gao W; Huang HC; Fitzgerald B; Fernsler D; Li JJ; Grandhi A; Liu H; Su FH; Wan S; Zeng Z; Chen HL; Dutko FJ; Nguyen BT; Wahl J; Robertson MN; Barr E; Yeh WW; Plank RM; Butterton JR; Esteban R
    Lancet Gastroenterol Hepatol; 2017 Nov; 2(11):805-813. PubMed ID: 28802816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mavyret and Vosevi--two new combinations for chronic HCV infection.
    Med Lett Drugs Ther; 2017 Oct; 59(1531):166-170. PubMed ID: 28977807
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparing the Frequencies of Contraindicated Drug-Drug Interactions Between Differing Antiretroviral Regimens in HIV-Infected Patients.
    Jakeman B; Nasiri M; Ruth L; Morse C; Mahatme S; Patel N
    Ann Pharmacother; 2017 May; 51(5):365-372. PubMed ID: 28367698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-drug interactions in anti-HCV therapy: a comparison among options available in Italy.
    Di Perri G; Cariti G
    Infez Med; 2019 Sep; 27(3):239-250. PubMed ID: 31545767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ledipasvir + sofosbuvir (Harvoni). A therapeutic advance in genotype 1 hepatitis C virus infection, despite uncertainties.
    Prescrire Int; 2015 Dec; 24(166):285-9. PubMed ID: 26788571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand.
    Sirinawasatien A; Techasirioangkun T
    PLoS One; 2020; 15(2):e0229517. PubMed ID: 32106270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan.
    Liu CH; Yu ML; Peng CY; Hsieh TY; Huang YH; Su WW; Cheng PN; Lin CL; Lo CC; Chen CY; Chen JJ; Ma Q; Brooks-Rooney C; Kao JH
    Aliment Pharmacol Ther; 2018 Dec; 48(11-12):1290-1300. PubMed ID: 30362139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration.
    Townsend K; Meissner EG; Sidharthan S; Sampson M; Remaley AT; Tang L; Kohli A; Osinusi A; Masur H; Kottilil S
    AIDS Res Hum Retroviruses; 2016 May; 32(5):456-62. PubMed ID: 26559180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease.
    García-Agudo R; Aoufi-Rabih S; Salgueira-Lazo M; González-Corvillo C; Fabrizi F
    Int J Artif Organs; 2018 Jul; 41(7):363-370. PubMed ID: 29582685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sofosbuvir/ledipasvir fixed-dose combination for treatment of chronic hepatitis C virus infection in children.
    Rizza SA; Nehra V; Temesgen Z
    Drugs Today (Barc); 2017 Aug; 53(8):447-451. PubMed ID: 29119149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short Communication: Relationship Between Contraindicated Drug-Drug Interactions and Subsequent Hospitalizations Among Patients Living with HIV Initiating Combination Antiretroviral Therapy.
    Sangiovanni RJ; Jakeman B; Nasiri M; Ruth L; Mahatme S; Patel N
    AIDS Res Hum Retroviruses; 2019 May; 35(5):430-433. PubMed ID: 30612438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A combination of ledipasvir and sofosbuvir (Harvoni) for hepatitis C.
    Med Lett Drugs Ther; 2014 Nov; 56(1455):111-2. PubMed ID: 25372848
    [No Abstract]   [Full Text] [Related]  

  • 18. Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes.
    Younossi ZM; Stepanova M; Sulkowski M; Naggie S; Puoti M; Orkin C; Hunt SL
    J Infect Dis; 2015 Aug; 212(3):367-77. PubMed ID: 25583164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug pricing: still a barrier to elimination of HCV.
    The Lancet Gastroenterology Hepatology
    Lancet Gastroenterol Hepatol; 2018 Dec; 3(12):813. PubMed ID: 30507462
    [No Abstract]   [Full Text] [Related]  

  • 20. Influence of Successful Chronic Hepatitis C Virus Treatment with Ledipasvir/Sofosbuvir on Warfarin Dosing Requirements in Four Veterans.
    Britnell SR; Willets AE; Vanderman AJ; Woodard CL; Britt RB
    Pharmacotherapy; 2016 Nov; 36(11):1173-1179. PubMed ID: 27716978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.